The estimated Net Worth of Peter N Kellogg is at least $13.5 Million dollars as of 4 May 2018. Mr. Kellogg owns over 3,500 units of Celgene stock worth over $5,492,798 and over the last 16 years he sold CELG stock worth over $1,767,332. In addition, he makes $6,239,180 as Executive Vice President and Chief Corporate Strategy Officer at Celgene.
Mr. Kellogg CELG stock SEC Form 4 insider trading
Peter has made over 20 trades of the Celgene stock since 2006, according to the Form 4 filled with the SEC. Most recently he exercised 3,500 units of CELG stock worth $378,210 on 4 May 2018.
The largest trade he’s ever made was exercising 60,000 units of Celgene stock on 31 July 2017 worth over $6,483,600. On average, Peter trades about 3,989 units every 47 days since 2003. As of 4 May 2018 he still owns at least 50,831 units of Celgene stock.
You can see the complete history of Mr. Kellogg stock trades at the bottom of the page.
Peter Kellogg biography
Peter N. Kellogg is Executive Vice President and Chief Corporate Strategy Officer of the Company effective August 1, 2018. Mr. Kellogg joined Celgene as Executive Vice President in July 2014. Before joining the Company, he was Chief Financial Officer and Executive Vice President of Merck & Co. Inc. from 2007 to 2014. From 2000 to 2007, Mr. Kellogg served as Chief Financial Officer and Executive Vice President of Finance (since 2003) at Biogen, Inc. Earlier in his career, Mr. Kellogg was a member of PepsiCo’s management for 13 years. He was the Senior Vice President, PepsiCo E-Commerce in 2000 and Senior Vice President and Chief Financial Officer, Frito-Lay International, from 1998 to 2000. Before that, Mr. Kellogg held various General Manager and Chief Financial Officer roles at Frito-Lay and Pepsi Cola in the US, Europe, Asia, and Latin America. Prior to joining PepsiCo, Mr. Kellogg was a senior consultant with Booz Allen & Hamilton and Arthur Andersen & Co. Since 2007, Mr. Kellogg has served on the Board of Directors of Yield10 (formerly Metabolix, Inc.), a public bioscience company focused on developing step change improvements to crop yields to enhance global food security. Mr. Kellogg received his BSE from Princeton University in 1978 and MBA from The Wharton School in 1982.
What is the salary of Peter Kellogg?
As the Executive Vice President and Chief Corporate Strategy Officer of Celgene, the total compensation of Peter Kellogg at Celgene is $6,435,520. There are 1 executives at Celgene getting paid more, with Mark Alles having the highest compensation of $13,116,000.
How old is Peter Kellogg?
Peter Kellogg is 62, he’s been the Executive Vice President and Chief Corporate Strategy Officer of Celgene since 2018. There are 7 older and 7 younger executives at Celgene. The oldest executive at Celgene Corp. is Ernest Mario, 80, who is the Independent Director.
What’s Peter Kellogg’s mailing address?
Peter’s mailing address filed with the SEC is 14 CAMBRIDGE CENTER, , CAMBRIDGE, MA, 02142.
Insider trading at Celgene
Over the last 16 years, insiders at Celgene have traded over $348,919,594 worth of Celgene stock and bought 171,908 units worth $10,354,899 . The most active insider traders include Sol J Barer, Robert J Hugin, and John W Jackson. On average, Celgene executives and independent directors trade stock every 13 days with the average trade being worth of $5,423,484. The most recent stock trade was executed by Jonathan Biller on 31 October 2019, trading 3,125 units of CELG stock currently worth $336,531.
What does Celgene do?
Celgene Corp. is an integrated global biopharmaceutical company, which engages in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases. Its primary commercial stage products include REVLIMID, POMALYST, IMNOVID, OTEZLA, ABRAXANE, and VIDAZA. The company was founded by David Stirling and Sol Barer in 1986 and is headquartered in Summit, NJ.
What does Celgene’s logo look like?
Complete history of Mr. Kellogg stock trades at Biogen, Celgene, Yield10 Bioscience, and Merck & Co
Celgene executives and stock owners
Celgene executives and other stock owners filed with the SEC include:
- Mark Alles, Chairman of the Board, Chief Executive Officer
- Peter Kellogg, Executive Vice President and Chief Corporate Strategy Officer
- Rupert Vessey, President – Research and Early Development
- Michael Casey, Lead Independent Director
- James Loughlin, Independent Director
- Ernest Mario, Independent Director
- Julia Haller, Director
- Carrie Cox, Independent Director
- Michael Bonney, Independent Director
- Richard Barker, Independent Director
- Michael Friedman, Independent Director
- John Weiland, Independent Director
- Patricia Hemingway Hall, Independent Director
- Hans Bishop, Director
- Jonathan Biller, Executive Vice President, General Counsel
- Alise Reicin, President – Global Clinical Development
- Terrie Curran, President, Global Inflammation & Immunology Franchise
- David Elkins, Chief Financial Officer, Executive Vice President
- Michael F. Pehl, See remarks
- Gerald Masoudi, Executive Vice President
- Gilla Phd Kaplan, Director
- Scott Andrew Smith, See Remarks
- Robert J Hugin, Chief Financial Officer
- Nadim Ahmed, PRES., HEMATOLOGY AND ONCOLOGY
- Lawrence V Stein, See Remarks
- Rodman L Drake, Chief Operating Officer
- Thomas O Daniel, see remarks
- Hoek Andre Van, Controller and CAO
- Walter L Robb, Director
- Graham Burton, See Remarks
- David W Gryska, Chief Financial Officer
- Aart Brouwer, See Remarks
- Sol J Barer, Chief Operating Officer
- Richard C E Morgan, Director
- Arthur H Jr Hayes, Director
- Thomas M Moriarty, see remarks
- Jacqualyn A Fouse, Chief Financial Officer
- Perry A Karsen, see remarks
- Jack L Bowman, Director
- Frank T Cary, Director
- John W Jackson, Chief Executive Officer
